By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – KeyGene and the National Center for Genome Resources, located in San Jose, NM, have inked a non-exclusive license agreement giving NCGR rights to market and conduct sequence-based mapping projects using KeyGene's Whole Genome Profiling (WGP) technology.

NCGR will combine its sequencing and informatics capabilities with the WGP technology, which is based on generating short read sequences of pooled BAC clones produced by KeyGene's partner Amplicon Express.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Among Sacks' books was "Awakenings," which was later made into an Academy Award-winning film.

The popularity of the #sciencemoviequote Twitter trend showcases scientists' eclectic movie tastes and knack for puns. 

The popular astrophysicist warned that apathy and even contempt for science in politics could lead to the end of informed democracy. 

In PLOS this week: Uncovering variants associated with diabetes-related kidney disease, a sequencing study of hepatitis E viruses circulating in Cambodia, and more.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Sep
24
Sponsored by
Personalis

This online seminar will outline a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. 

Oct
07
Sponsored by
Personal Genome Diagnostics

This webinar will highlight the key considerations and applications of next-generation sequencing for managing non-small cell lung cancer patients using plasma-based approaches. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.